{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:19:24Z","timestamp":1793812764151,"version":"4.6.1"},"reference-count":28,"publisher":"American Diabetes Association","issue":"8","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":2970,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Canagliflozin, a sodium glucose cotransporter (SGLT) 2 inhibitor, is also a low-potency SGLT1 inhibitor. This study tested the hypothesis that intestinal canagliflozin levels postdose are sufficiently high to transiently inhibit intestinal SGLT1, thereby delaying intestinal glucose absorption.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>This two-period, crossover study evaluated effects of canagliflozin on intestinal glucose absorption in 20 healthy subjects using a dual-tracer method. Placebo or canagliflozin 300 mg was given 20 min before a 600-kcal mixed-meal tolerance test. Plasma glucose, 3H-glucose, 14C-glucose, and insulin were measured frequently for 6 h to calculate rates of appearance of oral glucose (RaO) in plasma, endogenous glucose production, and glucose disposal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Compared with placebo, canagliflozin treatment reduced postprandial plasma glucose and insulin excursions (incremental 0- to 2-h area under the curve [AUC0\u20132h] reductions of 35% and 43%, respectively; P &amp;lt; 0.001 for both), increased 0- to 6-h urinary glucose excretion (UGE0\u20136h, 18.2 \u00b1 5.6 vs. &amp;lt;0.2 g; P &amp;lt; 0.001), and delayed RaO. Canagliflozin reduced AUC RaO by 31% over 0 to 1 h (geometric means, 264 vs. 381 mg\/kg; P &amp;lt; 0.001) and by 20% over 0 to 2 h (576 vs. 723 mg\/kg; P = 0.002). Over 2 to 6 h, canagliflozin increased RaO such that total AUC RaO over 0 to 6 h was &amp;lt;6% lower versus placebo (960 vs. 1,018 mg\/kg; P = 0.003). A modest (\u223c10%) reduction in acetaminophen absorption was observed over the first 2 h, but this difference was not sufficient to explain the reduction in RaO. Total glucose disposal over 0 to 6 h was similar across groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Canagliflozin reduces postprandial plasma glucose and insulin by increasing UGE (via renal SGLT2 inhibition) and delaying RaO, likely due to intestinal SGLT1 inhibition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc12-2391","type":"journal-article","created":{"date-parts":[[2013,2,14]],"date-time":"2013-02-14T23:50:03Z","timestamp":1360885803000},"page":"2154-2161","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":231,"title":["Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion"],"prefix":"10.2337","volume":"36","author":[{"given":"David","family":"Polidori","sequence":"first","affiliation":[{"name":"Janssen Research & Development, LLC, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Sha","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Raritan, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunder","family":"Mudaliar","sequence":"additional","affiliation":[{"name":"University of California, San Diego, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore P.","family":"Ciaraldi","sequence":"additional","affiliation":[{"name":"University of California, San Diego, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atalanta","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Raritan, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Vaccaro","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Raritan, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Farrell","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Raritan, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Rothenberg","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Raritan, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R.","family":"Henry","sequence":"additional","affiliation":[{"name":"University of California, San Diego, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2013,7,11]]},"reference":[{"key":"2022031222411032400_B1","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1038\/sj.ki.5002383","article-title":"Regulatory mechanisms of Na(+)\/glucose cotransporters in renal proximal tubule cells","volume":"Aug","author":"Lee","year":"2007","journal-title":"Kidney Int Suppl"},{"key":"2022031222411032400_B2","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.3748\/wjg.v12.i11.1657","article-title":"Intestinal sugar transport","volume":"12","author":"Drozdowski","year":"2006","journal-title":"World J Gastroenterol"},{"key":"2022031222411032400_B3","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol Rev"},{"key":"2022031222411032400_B4","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1210\/er.2010-0029","article-title":"Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes","volume":"32","author":"Abdul-Ghani","year":"2011","journal-title":"Endocr Rev"},{"key":"2022031222411032400_B5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2337\/db11-1029","article-title":"Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion","volume":"61","author":"Gorboulev","year":"2012","journal-title":"Diabetes"},{"key":"2022031222411032400_B6","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.1021\/jm100332n","article-title":"Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus","volume":"53","author":"Nomura","year":"2010","journal-title":"J Med Chem"},{"key":"2022031222411032400_B7","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1463-1326.2011.01406.x","article-title":"Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects","volume":"13","author":"Sha","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"2022031222411032400_B8","doi-asserted-by":"crossref","first-page":"e30555","DOI":"10.1371\/journal.pone.0030555","article-title":"Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models","volume":"7","author":"Liang","year":"2012","journal-title":"PLoS ONE"},{"key":"2022031222411032400_B9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1463-1326.2012.01558.x","article-title":"Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin","volume":"14","author":"Devineni","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"2022031222411032400_B10","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.2337\/dc11-1926","article-title":"Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031222411032400_B11","first-page":"S98","article-title":"Canagliflozin (sodium glucose co-transporter 2 [SGLT2] inhibitor): pharmacokinetics (PK) and pharmacodynamics (PD) in subjects with type 2 diabetes mellitus (T2DM)","volume":"91","author":"Devineni","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"2022031222411032400_B12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2125.1975.tb00568.x","article-title":"Inhibition of gastric emptying and drug absorption by narcotic analgesics","volume":"2","author":"Nimmo","year":"1975","journal-title":"Br J Clin Pharmacol"},{"key":"2022031222411032400_B13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2982.2001.00249.x","article-title":"Gastric emptying: the validity of the paracetamol absorption test adjusted for individual pharmacokinetics","volume":"13","author":"Medhus","year":"2001","journal-title":"Neurogastroenterol Motil"},{"key":"2022031222411032400_B14","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2337\/diacare.25.9.1597","article-title":"Intravenous glargine and regular insulin have similar effects on endogenous glucose output and peripheral activation\/deactivation kinetic profiles","volume":"25","author":"Mudaliar","year":"2002","journal-title":"Diabetes Care"},{"key":"2022031222411032400_B15","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1210\/jcem-34-5-876","article-title":"Alanine and gluconeogenesis in man: effect of ethanol","volume":"34","author":"Kreisberg","year":"1972","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031222411032400_B16","doi-asserted-by":"crossref","first-page":"580","DOI":"10.2337\/diab.34.6.580","article-title":"The disposal of an oral glucose load in healthy subjects. A quantitative study","volume":"34","author":"Ferrannini","year":"1985","journal-title":"Diabetes"},{"key":"2022031222411032400_B17","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1172\/JCI113489","article-title":"Skeletal muscle glycolysis, oxidation, and storage of an oral glucose load","volume":"81","author":"Kelley","year":"1988","journal-title":"J Clin Invest"},{"key":"2022031222411032400_B18","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0169-2607(02)00097-4","article-title":"A circulatory model for calculating non-steady-state glucose fluxes. Validation and comparison with compartmental models","volume":"71","author":"Mari","year":"2003","journal-title":"Comput Methods Programs Biomed"},{"key":"2022031222411032400_B19","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jpeds.2010.07.048","article-title":"Impaired glucose absorption in children with severe malnutrition","volume":"158","author":"Bandsma","year":"2011","journal-title":"J Pediatr"},{"key":"2022031222411032400_B20","doi-asserted-by":"crossref","first-page":"E532","DOI":"10.1152\/ajpendo.00127.2009","article-title":"Improved tolerance to sequential glucose loading (Staub-Traugott effect): size and mechanisms","volume":"297","author":"Bonuccelli","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031222411032400_B21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1210\/jc.2009-0473","article-title":"Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus","volume":"95","author":"Nair","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031222411032400_B22","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/ndt\/gfl175","article-title":"Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes\u2014results of a hyperglycaemic glucose clamp study","volume":"21","author":"Rave","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"2022031222411032400_B23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0026-0495(89)90129-7","article-title":"Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake","volume":"38","author":"DeFronzo","year":"1989","journal-title":"Metabolism"},{"key":"2022031222411032400_B24","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2337\/diab.37.6.667","article-title":"Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM","volume":"37","author":"DeFronzo","year":"1988","journal-title":"Diabetes"},{"key":"2022031222411032400_B25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5009\/gnl.2012.6.1.10","article-title":"Gut hormones and appetite control: a focus on PYY and GLP-1 as therapeutic targets in obesity","volume":"6","author":"De Silva","year":"2012","journal-title":"Gut Liver"},{"key":"2022031222411032400_B26","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.2337\/db06-S020","article-title":"Glucagon-like peptide 1 secretion by the L-cell the view from within","volume":"55","author":"Lim","year":"2006","journal-title":"Diabetes"},{"key":"2022031222411032400_B27","first-page":"159","article-title":"Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections","volume":"34","author":"Nauck","year":"1996","journal-title":"Z Gastroenterol"},{"key":"2022031222411032400_B28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0167-0115(03)00125-3","article-title":"GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine","volume":"114","author":"Mortensen","year":"2003","journal-title":"Regul Pept"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/36\/8\/2154\/618782\/2154.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/36\/8\/2154\/618782\/2154.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T19:57:00Z","timestamp":1647115020000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/36\/8\/2154\/33150\/Canagliflozin-Lowers-Postprandial-Glucose-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,11]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2013,7,11]]},"published-print":{"date-parts":[[2013,8,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc12-2391","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,11]]}}}